BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29313098)

  • 1. Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy.
    Kato S; Kawase M; Kato D; Ishida T; Uno M; Fujimoto Y; Masue T; Masue N; Deguchi T
    J Bone Miner Metab; 2019 Jan; 37(1):72-80. PubMed ID: 29313098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy.
    Wang W; Yuasa T; Tsuchiya N; Maita S; Kumazawa T; Inoue T; Saito M; Ma Z; Obara T; Tsuruta H; Satoh S; Habuchi T
    Endocr Relat Cancer; 2008 Dec; 15(4):943-52. PubMed ID: 18667685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
    Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
    Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
    Deng J; Li W; Yang L; Wang L; Zou D
    Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 33% radius evaluation to assess bone mineral density in prostate cancer patients.
    Morote J; Planas J; Mir MC; Raventós CX; Encabo G; Doll A
    World J Urol; 2011 Dec; 29(6):815-9. PubMed ID: 21191598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T; Maita S; Tsuchiya N; Ma Z; Narita S; Horikawa Y; Yamamoto S; Yonese J; Fukui I; Takahashi S; Hatake K; Habuchi T
    Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ; Srinivas S; Perkash I; Terris MK
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of androgen deprivation therapy on hip geometric properties and bone mineral density in Japanese men with prostate cancer and its relationship with the visceral fat accumulation.
    Watanabe D; Kimura T; Yamashita A; Minowa T; Miura K; Mizushima A
    Aging Male; 2020 Dec; 23(5):1158-1164. PubMed ID: 31959023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
    Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
    Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
    Deng JH; Yang LP; Wang LS; Zhou DF
    Asian J Androl; 2004 Mar; 6(1):75-7. PubMed ID: 15064839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    In Vivo; 2018; 32(2):409-412. PubMed ID: 29475929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan.
    Nishimoto H; Inui A; Mifune Y; Yamaura K; Bando Y; Okamura Y; Hara T; Terakawa T; Kuroda R
    Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674197
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
    Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.